keyword
https://read.qxmd.com/read/38397272/profound-hypoglycemia-and-high-anion-gap-metabolic-acidosis-in-a-pediatric-leukemic-patient-receiving-6-mercaptopurine
#21
Molly O'Shea, Alexis Kuhn, Ana L Creo, Mira Kohorst, Asmaa Ferdjallah
A 13-year-old male undergoing maintenance chemotherapy with methotrexate and 6-mercaptopurine (6MP), for very high-risk B-cell acute lymphoblastic leukemia (ALL), presented with vomiting due to severe hypoglycemia with metabolic acidosis. While his laboratory values were concerning for a critically ill child, the patient was relatively well appearing. Hypoglycemia is a rare but serious side effect of 6MP with an unexpectedly variable presentation; therefore, a high index of suspicion is needed for its prompt detection and treatment...
January 26, 2024: Children
https://read.qxmd.com/read/38384282/the-drug-survival-of-low-dose-thioguanine-in-patients-with-inflammatory-bowel-disease-a-retrospective-observational-study
#22
JOURNAL ARTICLE
Helena Gensmyr-Singer, Mårten Werner, Pontus Karling
BACKGROUND: Thiopurines are commonly used to treat inflammatory bowel disease but withdrawal due to side effects are common. Thioguanine has been suggested to be better tolerated than conventional thiopurines. OBJECTIVES: We studied drug-survival of low dose of thioguanine in real-life clinical practice in comparison to conventional thiopurines. DESIGN: Retrospective observational study. METHODS: All patients born 1956 and later, and who at least once started thiopurine treatment between 2006 and 2022 were included...
2024: Therapeutic Advances in Gastroenterology
https://read.qxmd.com/read/38356449/effects-of-allopurinol-on-6-mercaptopurine-metabolism-in-unselected-patients-with-pediatric-acute-lymphoblastic-leukemia-a-prospective-phase-ii-study
#23
JOURNAL ARTICLE
Jonatan Källström, Riita Niinimäki, Johan Fredlund, Hartmut Vogt, Laura Korhonen, Anders Castor, Josefine Palle, Arja Harila, Magnus Borssén, Jonas Abrahamsson, Torben Ek
Allopurinol can be used in maintenance therapy (MT) for pediatric acute lymphoblastic leukemia (ALL) to mitigate hepatic toxicity in patients with skewed 6- mercaptopurine metabolism. Allopurinol increases the erythrocyte levels of thioguanine nucleotides (e-TGN), which is the proposed main mediator of the antileukemic effect and decreases methyl mercaptopurine (e-MeMP) levels, associated with hepatotoxicity. We investigated the effects of allopurinol in thiopurine methyltransferase (TPMT) wild-type patients without previous clinical signs of skewed 6MP metabolism...
February 15, 2024: Haematologica
https://read.qxmd.com/read/38330760/a-stable-and-sensitive-2d-sers-sensor-for-bioanalytical-applications
#24
JOURNAL ARTICLE
Marianna Pannico, Pellegrino Musto
In this study, we describe a 2D-SERS sensor obtained by deposition of spherical gold nanoparticles (AuNPs) onto a suitably functionalized metal surface. Morphological analysis of the SERS surface by SEM and AFM demonstrated a uniform and stable distribution of the active nanoparticles. Following p-mercaptoaniline (pMA) functionalization, the sensor was characterized by co-localized Raman measurements, demonstrating a significant enhancement in Raman signals with homogeneous SERS activity across the entire sampled area...
February 1, 2024: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://read.qxmd.com/read/38280440/identification-of-fasudil-as-a-collaborator-to-promote-the-anti-tumor-effect-of-lenvatinib-in-hepatocellular-carcinoma-by-inhibiting-gli2-mediated-hedgehog-signaling-pathway
#25
JOURNAL ARTICLE
Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo
Lenvatinib is a frontline tyrosine kinase inhibitor for patients with advanced hepatocellular carcinoma (HCC). However, just 25% of patients benefit from the treatment, and acquired resistance always develops. To date, there are neither effective medications to combat lenvatinib resistance nor accurate markers that might predict how well a patient would respond to the lenvatinib treatment. Thus, novel strategies to recognize and deal with lenvatinib resistance are desperately needed. In the current study, a robust Lenvatinib Resistance index (LRi) model to predict lenvatinib response status in HCC was first established...
January 25, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38206358/retraction-note-6-mercaptopurine-reverses-experimental-vasospasm-and-alleviates-the-production-of-endothelins-in-no-independent-mechanism-a-laboratory-study
#26
Chih-Zen Chang, Shu-Chuan Wu, Aij-Lie Kwan, Chih-Long Lin, Shiuh-Lin Hwang
No abstract text is available yet for this article.
January 11, 2024: Acta Neurochirurgica
https://read.qxmd.com/read/38200353/retraction-note-6-mercaptopurine-exerts-an-immunomodulatory-and-neuroprotective-effect-on-permanent-focal-cerebral-occlusion-in-rats
#27
Chih-Zen Chang, Aij-Lie Kwan, Shen-Long Howng
No abstract text is available yet for this article.
January 11, 2024: Acta Neurochirurgica
https://read.qxmd.com/read/38137669/early-initiation-of-adalimumab-significantly-diminishes-postoperative-crohn-s-disease-endoscopic-recurrence-and-is-superior-to-6-mercaptopurine-therapy-an-open-label-randomized-controlled-study
#28
JOURNAL ARTICLE
Ayal Hirsch, Erez Scapa, Naomi Fliss-Isakov, Hagit Tulchinsky, Eran Itzkowitz, Yehuda Kariv, Yulia Ron, Henit Yanai, Ian White, Sharief Yassin, Nathaniel Aviv Cohen, Eli Brazovski, Iris Dotan, Nitsan Maharshak
Postoperative recurrence (POR) is the rule in patients with Crohn's disease (CD), mitigated with prophylactic therapy. The evidence for therapeutic choice and timing of intervention is lacking. We aimed to compare the rates of POR in patients treated early with prophylactic 6-mercaptopurine (6-MP) or adalimumab. We conducted a prospective single-center randomized open-label clinical study in which patients in surgical remission following their first ileocecectomy were randomized to receive early treatment with 6-MP or adalimumab...
December 10, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38125685/a-case-report-of-follicular-lymphoma-in-a-crohn-s-disease-patient-treated-with-azathioprine
#29
Nadeer Kottavadakkeel, Reefat Farzina, Arun Rajaram, Sathia Mannath, Abida Sunil
Inflammatory bowel disease (IBD) is an autoimmune disorder marked by chronic inflammation affecting the intestines. Crohn's disease (CD) and ulcerative colitis (UC) fall under the IBD umbrella, necessitating diverse treatments, including steroids, immunomodulators like 6-mercaptopurine (6-MP) and azathioprine (AZA), and biological agents. The prolonged use of immunomodulators, such as AZA, is associated with an elevated risk of developing lymphomas. This case report centers on a 77-year-old gentleman regularly monitored by Gastroenterology, undergoing long-term AZA therapy for CD management...
December 2023: Curēus
https://read.qxmd.com/read/38110844/bioequivalence-study-followed-by-model-informed-dose-optimization-of-a-powder-for-oral-suspension-of-6-mercaptopurine
#30
RANDOMIZED CONTROLLED TRIAL
Bhavatharini Arun, Mahendra Joshi, Archana Khosa Kakkar, Shivkumar Madki, Vijay Ivaturi, Girish Chinnaswamy, Shripad Banavali, Vikram Gota
BACKGROUND: 6-Mercaptopurine (6MP) is the mainstay chemotherapy for acute lymphoblastic leukemia (ALL) and is conventionally available as 50 mg tablets. A new 6MP powder for oral suspension (PFOS 10 mg/mL) was developed recently by IDRS Labs, India, intended for pediatric use. A comparative pharmacokinetics of PFOS with T. mercaptopurine was conducted to determine the dose equivalence. METHODS: An open-label, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study was conducted on 51 healthy adult subjects...
March 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38067375/double-hydroxyl-salt-as-smart-biocompatible-ph-responsive-carrier-for-6-mercaptopurine
#31
JOURNAL ARTICLE
Mariusz Sandomierski, Marcel Jakubowski, Maria Ratajczak, Adam Patalas, Katarzyna Gaweł-Bęben, Paulina Lechwar, Adam Voelkel
Hydroxy double salts are layered materials that are considered to be biocompatible. For this reason, research has been initiated on the possibility of their use in drug delivery. Despite their use for several types of drugs, their potential for controlled release of mercaptopurine (MERC) has not been studied. In this work, the synthesized hydroxy double salt (HDS) material was used as a carrier for this drug for the first time. The effectiveness of HDS synthesis has been proven by such techniques as X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM)...
November 30, 2023: Cancers
https://read.qxmd.com/read/38036847/determination-of-thiopurine-s-methyltransferase-tpmt-activity-in-human-erythrocytes-by-liquid-chromatography-tandem-mass-spectrometry-lc-ms-ms
#32
JOURNAL ARTICLE
Lie Li, Natalya Atkinson, Kristine R Crews, Alejandro R Molinelli
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme involved in the metabolism of thiopurine medications that are used in the treatment of multiple malignant and nonmalignant immunologic conditions. Polymorphisms in the TPMT gene associated with low enzyme activity can produce pronounced pharmacologic effects during therapy. The determination of TPMT erythrocyte activity is a valuable adjunct test to genotyping for the assignment of TPMT phenotype, especially in the presence of indeterminate genotypes...
2024: Methods in Molecular Biology
https://read.qxmd.com/read/38023976/concomitant-5-aminosalicylic-acid-treatment-does-not-affect-6-thioguanine-nucleotide-levels-in-patients-with-inflammatory-bowel-disease-on-thiopurines
#33
JOURNAL ARTICLE
Rahel Looser, Michael Doulberis, Jean-Benoit Rossel, Yannick Franc, Daniel Müller, Luc Biedermann, Gerhard Rogler
BACKGROUND: There are conflicting data as to whether co-treatment with 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) under azathioprine (AZA) or 6-mercaptopurine (6-MP) therapy may influence 6-thioguanine nucleotide (6-TGN) concentrations, and whether this combination puts patients at risk of side-effects. The aim of the study was to determine 6-TGN levels in patients treated with AZA/6-MP, either alone or in combination with 5-ASA. METHODS: Available blood samples from patients treated with AZA or 6-MP were retrieved from the Swiss IBD Cohort Study (SIBDCS)...
2023: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://read.qxmd.com/read/38001680/tooth-abnormalities-and-their-age-dependent-occurrence-in-leukemia-survivors
#34
JOURNAL ARTICLE
Anna Jodłowska, Lidia Postek-Stefańska
The multidrug nature of anticancer treatment and different treatment protocols used in the studies are likely to be a major limitation in establishing real risk factors determining the occurrence of dental abnormalities. The authors aimed to establish a relationship between the duration and the dose of chemotherapy and the number of tooth adverse effects in the group receiving the same treatment. Of the 40 anticancer therapy recipients who attended the outpatient dental clinic, 7 leukemia survivors receiving the treatment according to the ALL IC-BFM 2002 protocol were selected...
November 15, 2023: Cancers
https://read.qxmd.com/read/37988981/abcc4-impacts-megakaryopoiesis-and-protects-megakaryocytes-against-6-mercaptopurine-induced-cytotoxicity
#35
JOURNAL ARTICLE
Sabina Ranjit, Yao Wang, Jingwen Zhu, Satish B Cheepala, Erin G Schuetz, Woo Jung Cho, Beisi Xu, Camenzind G Robinson, Gang Wu, Anjaparavanda P Naren, John D Schuetz
The role of ABCC4, an ATP-binding cassette transporter, in the process of platelet formation, megakaryopoiesis, is unknown. Here, we show that ABCC4 is highly expressed in megakaryocytes (MKs). Mining of public genomic data (ATAC-seq and genome wide chromatin interactions, Hi-C) revealed that key megakaryopoiesis transcription factors (TFs) interacted with ABCC4 regulatory elements and likely accounted for high ABCC4 expression in MKs. Importantly these genomic interactions for ABCC4 ranked higher than for genes with known roles in megakaryopoiesis suggesting a role for ABCC4 in megakaryopoiesis...
November 8, 2023: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/37959208/the-role-of-pharmacogenetics-in-the-therapeutic-response-to-thiopurines-in-the-treatment-of-inflammatory-bowel-disease-a-systematic-review
#36
REVIEW
Aline C Ribeiro, Pâmela S A S Gerheim, Julio Maria Fonseca Chebli, Jorge Willian L Nascimento, Priscila de Faria Pinto
This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy...
October 25, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37945367/recurrence-of-metastatic-crohn-s-disease-after-surgical-resection
#37
JOURNAL ARTICLE
Alexander Sherban, Matthew Keller
A 36-year-old woman presented to the emergency department with a 1-day history of purulent perianal and vulvar discharge. She had a 25-year history of Crohn's disease (CD), and 13 years prior had received a total colectomy with end ileostomy. She had vulvar biopsies 5 years prior to presentation, demonstrating noncaseating granulomas consistent with metastatic Crohn's disease (MCD). Throughout the course of her disease, she had a failed treatment with adalimumab, certolizumab, methotrexate, and 6-mercaptopurine...
2023: Skinmed
https://read.qxmd.com/read/37892708/incidence-of-myelotoxicity-and-other-adverse-effects-related-to-thiopurine-starting-in-patients-with-inflammatory-bowel-disease-retrospective-observational-study-in-a-third-level-hospital
#38
JOURNAL ARTICLE
Gerard Grau, Eduard Brunet-Mas, Laura Patricia Llovet, Patricia Pedregal, Albert Villoria, Luigi Melcarne, Anna Puy, Belen Garcia-Sague, Luis Enrique Frisancho, María José Ramírez-Lázaro, Sergio Lario, Xavier Calvet
BACKGROUND AND OBJECTIVES: Thiopurines are an effective treatment for the maintenance of remission in inflammatory bowel disease (IBD). They can present adverse effects (AEs), with myelotoxicity being the most relevant. This study aims to determine the incidence of AEs related to the starting of thiopurines in our centre. METHODOLOGY: Retrospective study. The AEs in patients that were started on thiopurines between January 2016 and June 2020 were registered, with a two-year follow-up...
October 17, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37891257/single-versus-intermittent-cycle-exposure-effect-of-6-mercaptopurine-in-juvenile-sprague-dawley-rat-a-germ-cell-specific-mechanistic-study
#39
JOURNAL ARTICLE
Archna Panghal, Gopabandhu Jena
Infertility is a frequent long-term adverse effect of cancer therapy for children. Compromised testicular functions in adolescence are frequent observations after chemotherapy and there are currently no well-established alternatives to avoid this damage. Antimetabolites such as 6-mercaptopurine (6-MP) are used to treat a variety of cancer; however, its treatment-associated adverse effects on the male reproductive functions are overlooked. Here, the molecular processes underlying 6-MP-induced male germ cell damage in juvenile Sprague-Dawley (SD) rats (3 weeks) have been investigated...
October 28, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/37888780/severe-myelosuppression-involving-hpv-b19-infection-and-nudt15-polymorphisms-during-therapy-for-lch
#40
JOURNAL ARTICLE
Hiroki Hosokawa, Hironobu Kitazawa, Nobuhiro Akita, Nao Yoshida, Asahito Hama
No abstract text is available yet for this article.
2023: Pediatrics International: Official Journal of the Japan Pediatric Society
keyword
keyword
20140
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.